Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...
Roche reports positive phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity: Basel Wednesday, January 28, 2026, 10:00 Hrs [IST] Roche anno ...
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...
In this study, researchers matched patients using GLP-1RA therapy to those using aspirin to compare colorectal cancer incidence in each population.
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...
Everyday Health on MSN
Do oral GLP-1 drugs work as well as injectables? We checked the science
FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits. There are differences, however.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results